Search Results

Rheonix Inc., a manufacturer of a highly advanced microfluidic molecular testing platform, announced the opening of Rheonix Laboratories LLC, a CLIA-certified clinical laboratory located in Ithaca, New York.

Rheonix Inc. announced today that the United States Food and Drug Administration (FDA) has issued an expanded Emergency Use Authorization (EUA) for the Rheonix COVID-19™ MDx Assay to include home collection using the Rheonix Laboratories COVID-19 PCR Test Saliva Home Collection Kit.

Rheonix Inc., an innovative leader in highly multiplexed pathogen detection, announced the appointment of Stephen J. Thomas, M.D., as Chief Medical Officer and member of the Rheonix Board of Directors.

Rheonix Inc. today announced that the Rheonix COVID-19™ MDx Assay will detect the newly emerging omicron variant of SARS-CoV-2, as well as other variants of public health concern.

New additions to the Rheonix board of directors add expertise in infectious diseases, laboratory medicine and health system leadership

Rheonix Inc . Receives FDA Emergency Use Authorization for Rapid, Fully Automated Molecular COVID-19 Test

Rheonix Inc., an innovative leader in highly multiplexed pathogen detection, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of its automated Encompass MDx® Workstation, along with its STI TriPlex™ Assay and Male Urine Collection Kit for the detection of sexually transmitted infections (STI).

Rheonix Inc. announced today that the United States Food and Drug Administration (FDA) has issued an expanded Emergency Use Authorization (EUA) for the Rheonix COVID-19™ MDx Assay and now allows the use of saliva as an approved sample type. The fully automated sample-to-answer assay was initially authorized for use on a range of respiratory specimens under EUA on April 29, 2020. The ability to test saliva samples for